Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health. The Company is based in Waltham, MA and San Diego, CA. For more information, visit www.kailera.com.
Location: United States
Total raised: $1B
Investors 2
| Date | Name | Website |
| 16.12.2025 | Bain Capit... | baincapita... |
| 04.10.2024 | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.10.2025 | Series B | $600M | Bain Capit... |
| 07.10.2024 | Series A | $400M | - |
Mentions in press and media 7
| Date | Title | Description |
| 14.10.2025 | Kailera taps Bain-led syndicate for $600M to carry Zepbound challenger into phase 3 | Kailera Therapeutics has raised $600 million to take its lead obesity program into phase 3. The series B round continues the meteoric rise of Kailera, which exited stealth with $400 million and ex-China rights to a clutch of obesity candida... |
| 04.04.2025 | This Is the Overlooked Industry You Should Start Investing in Now Learn about the rapidly growing healthtech sector, including key investment areas, potential risks and future trends, to make informed... | In 2019, a ground-breaking procedure took place in Sanya, China, where a surgeon used state-of-the-art surgery tools to implant a stimulation device into the brain of a Parkinson's patient. Why is this so remarkable, you ask? The patient wa... |
| 01.11.2024 | The 10 Biggest Rounds Of October: OpenAI’s Massive Deal Dwarfs All Others | 2 Shares Email Facebook Twitter LinkedIn This is a monthly feature that runs down the month’s top 10 funding rounds in the U.S. Check out September’s biggest rounds here. OpenAI led the way last month and it really wasn’t even close. Howeve... |
| 07.10.2024 | Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For Obesity | Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million... |
| 01.10.2024 | Kailera Therapeutics Launches with $400M in Series A Financing | Kailera Therapeutics, a Boston, MA-based clinical-stage biopharmaceutical company, launched with $400M in Series A funding. The round was led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments, with participation from Lyra Ca... |
| 01.10.2024 | Kailera launches with $400M series A and clutch of Chinese obesity drugs | Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China and $400 million in series A funds. The Massachusetts- and California-based biotech is led by former Cerevel Therap... |
| - | Kailera Therapeutics | “Kailera is advancing a broad and differentiated portfolio of clinical-stage injectable and oral GLP-1 therapies for obesity and related conditions.” |